Valuation: Phosphagenics Limited

Market Cap 84.27M 58.84M 51.42M 47.45M 43.74M 82.44M 5.67B 567M 223M 2.78B 221M 216M 9.55B P/E 2024
-2.5x
P/E 2025 -6.43x
Enterprise Value 79.62M 55.6M 48.59M 44.83M 41.33M 77.89M 5.35B 536M 211M 2.62B 209M 204M 9.03B EV / Sales 2024
5.85x
EV / Sales 2025 23x
Free-Float
76.76%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer - 30/04/2020
Chief Operating Officer - 30/04/2020
Corporate Secretary - 30/04/2026
Director TitleAgeSince
Director/Board Member - 12/04/2015
Chairman - 31/12/2018
Director/Board Member 59 25/04/2024
Change 5-day change 1-year change 3-year change Capi.($)
-14.29%-14.29% - - 58.84M
+0.85%-0.80%+52.79%+161.33% 1,051B
+1.23%-1.53%+54.58%+59.08% 609B
+0.04%+2.58%+34.47%+86.33% 450B
+0.78%-0.71%+29.28%+24.10% 330B
+1.41%+0.58%+35.44%+40.67% 284B
-0.27%-1.87%+22.34%+22.51% 263B
-1.76%+2.37%-20.43%-38.00% 223B
-1.42%+0.80%+24.27%+57.50% 198B
-1.48%+3.43%+24.08%+71.67% 167B
Average -1.49%+0.54%+28.54%+53.91% 397.23B
Weighted average by Cap. +0.37%+0.02%+37.51%+79.63%

Financials

2024 2025
Net sales 1.13M 791K 691K 638K 588K 1.11M 76.17M 7.62M 3M 37.3M 2.97M 2.91M 128M 1.24M 864K 755K 697K 642K 1.21M 83.23M 8.33M 3.28M 40.76M 3.25M 3.17M 140M
Net income -3.12M -2.18M -1.91M -1.76M -1.62M -3.05M -210M -21.01M -8.26M -103M -8.19M -8.01M -354M -4.42M -3.08M -2.7M -2.49M -2.29M -4.32M -297M -29.73M -11.69M -145M -11.58M -11.33M -501M
Net Debt -1.3M -906K -792K -731K -674K -1.27M -87.27M -8.74M -3.44M -42.74M -3.4M -3.33M -147M -4.65M -3.25M -2.84M -2.62M -2.41M -4.55M -313M -31.29M -12.31M -153M -12.19M -11.92M -527M
Logo Phosphagenics Limited
Avecho Biotechnology Limited is an Australia-based biopharmaceutical company. The Company develops and commercializes human and animal health products using its proprietary drug delivery system called Tocopheryl Phosphate Mixture (TPM). TPM is derived from Vitamin E using proprietary and patented processes. The Company's segments include Production and Human Health. The Production segment manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health portfolio covers delivery of pharmaceutical products through gels, injectables and patches, including conduct of research and development activities. The Company's products pipeline includes Weaner Pig Starter TPM Premix, Poultry TPM Premix, Dairy TPM Premix, Daptomycin, Propofol, Veterinary Applications, among others. Its TPM products are commercialized under license: Voveran TPM Gel, Instanac TPM Gel, Vital ET, and Ashland TPM.
Employees
-